TY - BOOK AU - Rai,Mahendra AU - Kon,Kateryna Volodymyrivna TI - Nanotechnology in diagnosis, treatment and prophylaxis of infectious diseases SN - 9780128014714 AV - RC113.3 U1 - 616.90475 23 PY - 2015///] CY - London PB - Academic Press is an imprint of Elsevier KW - Communicable diseases KW - Diagnosis KW - Technological innovations KW - Treatment KW - Nanomedicine KW - Nanotechnology KW - methods KW - Communicable Disease Control KW - Communicable Diseases KW - therapy KW - Drug Resistance, Microbial KW - Antibiotics KW - Bacterial diseases KW - Chemotherapy KW - HEALTH & FITNESS KW - Diseases KW - Contagious KW - bisacsh KW - MEDICAL KW - Infectious Diseases KW - Electronic books N1 - Includes bibliographical references and index; Front Cover; Nanotechnology in Diagnosis, Treatment and Prophylaxis of Infectious Diseases; Copyright Page; Contents; List of Contributors; Preface; 1 Gold and Silver Nanoparticles for Diagnostics of Infection; 1.1 Nanotechnology and Infection; 1.2 Gold and Silver NPs for Molecular Diagnostics; 1.2.1 Biomarkers; 1.3 Nanodiagnostics for Nucleic Acids; 1.3.1 Homogeneous Colorimetric Assays; 1.3.1.1 Unmodified NPs; 1.3.1.2 Cross-Linking; 1.3.1.3 Noncross-Linking; 1.3.2 Heterogeneous Detection; 1.3.2.1 Microarrays; 1.3.2.2 Lateral Flow Assays; 1.3.3 Electrochemical Assays; 1.3.4 Fluorescence Assays1.3.5 Raman and SERS; 1.3.6 Other; 1.4 Aptamers and Antibodies; 1.4.1 Colorimetric; 1.4.2 Electrochemical; 1.4.3 Lateral Flow Assays; 1.5 iPCR and Other Methods; 1.6 Conclusion; References; 2 Antimicrobial Models in Nanotechnology: From the Selection to Application in the Control and Treatment of Infectious Diseases; 2.1 Introduction; 2.2 Antimicrobial Susceptibility Testing Methods of NMs; 2.2.1 Broth Dilution Test; 2.2.2 Spectrophotometric Measurement; 2.2.3 Cell Counting; 2.2.4 Colorimetric and Fluorescent Assays; 2.2.5 In Vitro Infection Animal Model; 2.2.6 Biocidal Testing2.2.7 Antibiofilm Activity; 2.2.8 Quorum-Sensing Inhibitors; 2.2.9 Microbial Membrane Lysis; 2.2.10 Microbial Oxidative Stress; 2.2.11 Antipersister and Antidormancy Bacterial Cells; 2.2.12 Microbial Fitness; 2.3 Nanotoxicology; 2.3.1 Nano-Genotoxicology; 2.3.2 Cytotoxicity; 2.3.3 Immunotoxicity; 2.3.4 In Vitro Skin Irritation; 2.3.5 Caenorhabditis elegans Toxicity Model; 2.3.6 Nanotoxicity in Embryonic and Adult Zebrafish; 2.3.7 Bioluminescence-Based Nanotoxicity Test; 2.4 In Vitro Pharmacokinetics/Pharmacodynamic Models; 2.4.1 Particokinetics; 2.4.2 Caco-2 Permeability; 2.4.3 Hollow Fiber System2.5 Conclusions; References; 3 Silver Nanoparticles for the Control of Vector-Borne Infections; 3.1 Introduction; 3.2 Louse-Borne Infections and Activity of AgNPs Against Lice; 3.3 Mosquito-Borne Infections and Activity of AgNPs Against Mosquitoes; 3.4 Tick-Borne Infections and Activity of AgNPs Against Ticks; 3.5 Flies, Their Role in Transmission and Spread of Infections, and Activity of AgNPs Against Flies; 3.6 Conclusions and Future Prospects; References; 4 Magnetite Nanostructures: Trends in Anti-Infectious Therapy; 4.1 Introduction; 4.2 Nanoparticles with Biomedical Applications4.2.1 Design of Tailored Magnetic Nanoparticles with Applications in Microbiology; 4.2.2 Magnetite Nanoparticles Used to Control Microorganisms Attachment and Biofilm Formation; 4.2.3 The Biocompatibility of Magnetite Nanoparticles; 4.2.3.1 Biocompatibility Evaluation of Magnetite Nanoparticles at the Cellular Level; 4.2.3.2 Biocompatibility Evaluation of Magnetite Nanoparticles at Biochemical and Molecular Level; 4.2.3.3 Biocompatibility Evaluation of Magnetite Nanoparticles Using Animal Models; 4.3 Conclusions; References UR - https://eresourcesptsl.ukm.remotexs.co/user/login?url=http://www.sciencedirect.com/science/book/9780128013175 ER -